Effect of Treatment With Biologic Agents on the Novel Inflammatory Biomarkers Systemic Immune Inflammation Index and Systemic Inflammation Response Index for Psoriasis
Dermatology Practical & Conceptual · 31.01.2024 · e2024065
DOI: 10.5826/dpc.1401a65 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 31.01.2024. Verfasst von Funda Tamer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Gazi University School of Medicine, Ankara, Turkey. Die Arbeit wurde bisher 21-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Psoriasis is a chronic cutaneous disorder with underlying systemic inflammation. The systemic immune inflammation (SII) and systemic inflammation response indexes (SIRI) are novel biomarkers that indicate systemic inflammation.
Objectives
We aimed to evaluate the effect of biological agent treatment on SII and SIRI in psoriasis patients.
Methods
Between April 2019 and October 2022, SII and SIRI were retrospectively evaluated in patients with psoriasis before and three months after the initiation of biological agents.
Results
This study included 220 patients, 101 females and 119 males. SIRI was significantly higher in male patients compared to females (P < 0.001). Although not statistically significant, SII and SIRI were higher in obese patients, patients with severe psoriasis, longer disease duration, nail involvement and patients who received previous biological agent treatment. SII was also higher in patients with hypertension, diabetes, hepatic steatosis, depression and coronary artery disease (P = 0.801, P = 0.752, P = 0.706, P = 0.079, P = 0.861, respectively), whereas SIRI was higher in patients with diabetes and depression (P = 0.263, P = 0.777, respectively). Both SII and SIRI statistically significantly decreased after treatment with adalimumab, infliximab, ixekizumab, secukinumab, ustekinumab and risankizumab.
Conclusions
SII and SIRI may indicate the severity of psoriasis as well as SII may be associated with psoriatic arthritis, hypertension, hepatic steatosis and coronary artery disease in patients with psoriasis. There is no consensus on the biomarkers that can be used to create an optimized treatment strategy in psoriasis. Therefore, SII and SIRI may be helpful in making the choice of treatment and in the follow-up of patients with psoriasis treated with biological agents.
Autor:innen und Institutionen
- Department of Dermatology, Gazi University School of Medicine, Ankara, Turkey.
Zitieren
APA
Tamer, F., Edek, Y. C., & Aksakal, A. B. (2024). Effect of Treatment With Biologic Agents on the Novel Inflammatory Biomarkers Systemic Immune Inflammation Index and Systemic Inflammation Response Index for Psoriasis. Dermatology Practical & Conceptual, e2024065. https://doi.org/10.5826/dpc.1401a65
Vancouver
Tamer F, Edek YC, Aksakal AB. Effect of Treatment With Biologic Agents on the Novel Inflammatory Biomarkers Systemic Immune Inflammation Index and Systemic Inflammation Response Index for Psoriasis. Dermatology Practical & Conceptual. 2024:e2024065. doi:10.5826/dpc.1401a65
BibTeX
@article{Tamer2024,
author = {Tamer, Funda and Edek, Yusuf Can and Aksakal, Ahmet Burhan},
title = {Effect of Treatment With Biologic Agents on the Novel Inflammatory Biomarkers Systemic Immune Inflammation Index and Systemic Inflammation Response Index for Psoriasis},
journal = {Dermatology Practical & Conceptual},
year = {2024},
pages = {e2024065},
doi = {10.5826/dpc.1401a65}
}
EUVIMED